OSLO, Norway, Dec. 4, 2019 /PRNewswire/ -- Phoenix Solutions
AS, a clinical-stage biotech company, today announced the
appointment of Dr. Jean-Michel Cosséry to its Board of
Directors.
"We are very pleased to welcome Dr. Jean-Michel Cosséry to the
Board of Phoenix," says Dr.
Per Sontum, CEO of Phoenix. "Jean-Michel has a unique combination
of experience spanning across diagnostics and therapeutics, with
global leadership roles within research, marketing and
commercialization in leading healthcare organizations. His
knowledge of the field of oncology will be invaluable to
Phoenix and we look forward to
Jean-Michel's contribution to the strategic, clinical and
commercial development of our proprietary Acoustic Cluster Therapy
technology (ACT®)."
Jean-Michel comments, "I am delighted to join the Board of
Phoenix at the stage when the
company has already taken its first steps into clinical development
within oncology. Within this field, there is a range of unmet
clinical needs and I believe increased, localized delivery of
cytotoxic drugs can make a significant difference in many of these.
I also see great potential for ACT® in the treatment of local
pathologies within a range of other therapeutic areas."
About Dr. Jean-Michel Cosséry
Jean-Michel is a senior healthcare executive with global
leadership experience in research, marketing and commercial roles
within med-tech and pharmaceuticals in six countries. Jean-Michel
worked in Novartis and Serono before joining GE Healthcare ("GHEC")
as the Chief Marketing Officer and Vice-President Global Marketing.
He represented GEHC at the GE Commercial Council and he was a
member of the board for the Wipro-GE Healthcare joint venture in
India.
More recently, Jean-Michel was with Eli-Lilly acting as
Vice-President, North American Oncology, as well as Managing
Director Northern Europe (including the U.K. and Ireland). Externally, Jean-Michel represented
Lilly in the CEO Forum in Washington,
D.C., was a board member of the ABPI and the Chairman of the
Board of the American Pharmaceutical Group.
Today, Jean-Michel serves as a Non-Executive Director on the
boards of Malin Corporation plc, Kymab Ltd and Immunocore
Ltd.
Jean-Michel holds an MBA from the Rotterdam School of Management
(Erasmus University), The Netherlands. He received his Ph.D. with
honors in Nuclear Chemistry and Neurobiology from University
Paris, France, and conducted
post-doctoral research in Neuropharmacology at the NIH in
the United States. Additionally,
he holds a Pharm D with honors in Pharmacology from the University
of Paris.
About Phoenix Solutions AS
Phoenix Solutions is a clinical-stage Norwegian biotech
company spun out of GE Healthcare in 2012, currently developing a
technology platform for targeted drug delivery – Acoustic
Cluster Therapy (ACT®). ACT® is a unique approach to
ultrasound-mediated, targeted drug delivery – capable of
enhancing significantly the clinical utility of a wide range of
therapeutic molecules and nano-drugs for a wide range of clinical
indications. Its primary mode of action is in defeating the
vascular barrier, enhancing extravasation, distribution and uptake
of drug in the targeted tissue, thereby increasing efficacy and/or
reducing toxicity.
ACT® is generally indicated towards diseases where current
clinical practice treats known, localized pathologies (e.g., solid
tumors) with medicinal therapy, and where Standard of Care is being
limited from an inability to deliver sufficiently high
concentrations of drug without excessive systemic
toxicity.
ACT® has shown extremely promising results in a series of
pre-clinical evaluations, including treatment of colon, breast,
pancreatic and prostate cancers, with a wide range of cytotoxic
drugs. Phoenix is currently
pursuing pre-clinical development exploring synergies between ACT®
and immune-oncology drugs as well as within other medicinal
segments such as CNS and infectious diseases.
Phoenix is currently in
clinical development within the oncology segment at The Royal
Marsden Hospital (U.K.). In their First in Man "ACTivate"-trial
(NCT04021277), ACT® is investigated in combination with Standard of
Care chemotherapies for treatment of hepatic metastases associated
with colorectal and pancreatic cancers.
Disclaimer
This media statement contains certain forward-looking
statements relating to the business, financial performance and
results of Phoenix Solutions AS, their proprietary ACT technology,
the ACTivate trial and/or the industry in which it operates.
Forward-looking statements concern future circumstances and results
and other statements that are not historical facts, sometimes
identified by the words
"believes," "expects," "intends," "anticipates," "targets," and
similar expressions. The forward-looking statements contained in
this statement, including assumptions, opinions and views of the
company or cited from third-party sources are solely opinions and
forecasts, which are subject to risks, uncertainties and other
factors that may cause actual events to differ materially from any
anticipated development. Neither the company nor any of its
Directors, officers or employees provide any assurance that the
assumptions underlying such forward-looking statements are free
from errors nor do any of them accept any responsibility for the
future accuracy of the opinions expressed in this statement or the
actual occurrence of the forecasted developments.
The Company assumes no obligation, except as required by law,
to update any forward-looking statements or to conform these
forward-looking statements to our actual results.
Media Contact:
CEO Dr. Per Christian Sontum
Email: per.sontum@phoenixsolutions.no
View original
content:http://www.prnewswire.com/news-releases/phoenix-solutions-as-strengthens-its-board-with-the-appointment-of-dr-jean-michel-cossery-300969540.html
SOURCE Phoenix Solutions AS